Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

873
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
873
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

403
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
403
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

576
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
576
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

801
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
801
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

403
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
403
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

703
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
703

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variations in Healthcare Provider Interactions and Treatment Satisfaction by Patient Race and Ethnicity: A Survey of Adults with Atopic Dermatitis.

Advances in therapy·2026
Same author

The Evolution of Colorectal Surgery Training.

Clinics in colon and rectal surgery·2026
Same author

Management of Percutaneous Cholecystostomy Drains: A Consensus Statement.

JAMA network open·2026
Same author

Management of percutaneous cholecystostomy drains: a survey of real-world practices across Ireland and the UK.

World journal of emergency surgery : WJES·2026
Same author

EPICERTIN, an engineered variant of cholera toxin B subunit, promotes survival and a pro-remodeling macrophage phenotype for mucosal healing in colitis.

Mucosal immunology·2026
Same author

What Happens After Declining Recommended Surgery? Analysis of Early-Stage Non-Small Cell Lung Cancer.

Annals of thoracic surgery short reports·2025

Related Experiment Video

Updated: Dec 31, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.3K

Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Vanessa States1, Stephen O'Brien1, Jayesh P Rai2

  • 1Price Institute of Surgical Research, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville, 550 South Jackson Street, Louisville, KY, 40202, USA.

Digestive Diseases and Sciences
|January 12, 2020
PubMed
Summary
This summary is machine-generated.

Pyoderma gangrenosum (PG) is a severe manifestation of inflammatory bowel disease (IBD). This study confirms PG is linked to female gender, Crohn's disease, erythema nodosum, and ocular EIMs.

Keywords:
Extra-intestinal manifestationsInflammatory bowel diseaseMeta-analysisPyoderma gangrenosumSystematic review

More Related Videos

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.6K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

327

Related Experiment Videos

Last Updated: Dec 31, 2025

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.3K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

68.6K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

327

Area of Science:

  • Gastroenterology
  • Dermatology
  • Clinical Epidemiology

Background:

  • Pyoderma gangrenosum (PG) is an uncommon but severe extra-intestinal manifestation (EIM) of inflammatory bowel disease (IBD).
  • The incidence and risk factors for PG in IBD patients are not well-established.

Purpose of the Study:

  • To assess the incidence of PG in IBD patients.
  • To identify factors associated with PG development in IBD patients.

Main Methods:

  • A systematic literature search of electronic databases (PubMed, Ovid) from 1966 to 2019.
  • Inclusion of 14 studies and a meta-analysis of 61,695 IBD patients, including a review of an institutional cohort of 1057 IBD patients.
  • Multivariate regression and random effects models were used to identify risk factors and combine data.

Main Results:

  • The cumulative cohort included 379 PG cases out of 61,695 IBD patients, with incidence ranging from 0.4% to 2.6% in individual studies.
  • Significant risk factors identified in the meta-analysis include female gender, Crohn's disease, erythema nodosum, and ocular EIM.
  • Ocular EIMs and permanent stoma were significant risk factors in the institutional cohort.

Conclusions:

  • This meta-analysis confirms associations between PG and female gender, Crohn's disease, erythema nodosum, and ocular EIM.
  • Findings contribute to understanding PG as a significant EIM in IBD.
  • Highlights the need for further research into PG pathogenesis and management in IBD.